Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.

about

Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.

Item

http://www.wikidata.org/entity/Q55365709

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Value assessment in oncology d ...... tatic breast cancer in Canada.

@en

Value assessment in oncology d ...... tatic breast cancer in Canada.

@nl

type

Item

label

Value assessment in oncology d ...... tatic breast cancer in Canada.

@en

Value assessment in oncology d ...... tatic breast cancer in Canada.

@nl

prefLabel

Value assessment in oncology d ...... tatic breast cancer in Canada.

@en

Value assessment in oncology d ...... tatic breast cancer in Canada.

@nl

P1476

Value assessment in oncology d ...... tatic breast cancer in Canada.

@en

P2093

J Lemieux

http://www.w3.org/2001/XMLSchema#string

S Audet

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

P304

S161-S170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.25.3846

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29910659

http://www.w3.org/2001/XMLSchema#string

P921

Canada

P932

6001763

http://www.w3.org/2001/XMLSchema#string